Company Overview of InnoPharma, Inc.
InnoPharma, Inc., a sterile product development company, engages in the development of generic and specialty pharmaceutical products in the form of pen and depot injectables, and ophthalmic dosage. It offers therapeutic drugs for respiratory, anti-cancer, anti-viral, hormones, critical care, CNS, anti-psychotic, and anti-arrhythmic categories; and vitamin D injections, and antagonist tablets. It also develops formulations, which include solutions, suspensions, lyophilized, emulsions, liposomes, micelles, and lipid complexes; small molecules with solubility and stability challenges; polypeptides and carbohydrates; and novel formulations of existing drugs, including hard-to-make products in th...
10 Knightsbridge Road
Piscataway, NJ 08854
Founded in 2005
Key Executives for InnoPharma, Inc.
Senior Director of Finance
Scientific Officer and Executive Director
Vice President of Business Development & Alliance Management
Compensation as of Fiscal Year 2014.
InnoPharma, Inc. Key Developments
InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN
Aug 29 14
InnoPharma Inc. announced the approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for decitabine for injection, a generic version of Eisai Inc.'s DACOGEN(R). InnoPharma developed the generic formulation of decitabine for injection and entered into an agreement with Sandoz Inc., pursuant to which Sandoz will sell, market and distribute decitabine for injection in the United States. According to IMS data, aggregate U.S. sales of DACOGEN were approximately $251 million for the twelve months ending in April 2014. Decitabine for injection is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. Decitabine for injection will be marketed in 20 mL single dose glass vials containing 50 mg decitabine, the same size and strength as the brand. The dosing regimen is identical to the brand.
Sandoz Canada to Make, Use, Sell, Market and Distribute InnoPharma's Olanzapine Injection in Canada
Jul 30 14
InnoPharma Inc. announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa(R) injection), in Canada. Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania. As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada.
InnoPharma, LLC Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 08:00 AM
Dec 9 13
InnoPharma, LLC Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-15-2014 08:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Navneet Puri, Founder, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 16, 2014